References
- Kuklina EV, Agal C, Callagham WM. Hypertensive disorders and severe obstetric morbidity in the United States. Obstet Gynecol 2009;113:1299–306.
- Ananth CV, Keyes KM, Waqner RJ. Preeclampsia rates in the United states 1980–2010 age-period-cohort analysis. Br J Med 2013;347: f 65–64.
- Li R, Tsogas Z, Callagham WM. Health and economic burden of preeclampsia: no time for complacency. Am J Obstet Gynecol 2017;217:235–6.
- Stevens W, Shita T, Incerti D, et al. Short term costs of preeclampsia to the United States health care system. Am J Obstet Gynecol 2017;217:237–48.
- Salomon C, Guarzon D, Scholz-Romero K, et al. Placental exosomes as early biomarker of preeclampsia: potential role of exosomal microRNAs across gestation. J Clin Endocrinol Metab 2017;102: 3182–94.
- Stanhewicz AE, Jandu SA, Alexander LM. Increased angiotensin II sensitivity contributes to microvascular dysfunction in women who have had preeclampsia. J Hypertension 2017;70:382–9.
- Sciferes CM, Parks TW, Feghali M, et al. Placental maternal vascular malperfusion and adverse pregnancy outcome in gestational diabetes. Placenta 2017;49:10–5.
- Cartwright JE, Keogh RJ, Tissot Van Patot MC. Hypoxia and placental remodelling. Adv Exp Med Biol 2007;618:113–26.
- Donaghay M, Lessey BA. Uterine receptivity: alterations associated with benign gynecological disease. Semin Reprod Med 2007;25:461–75.
- Gellesen B, Reimann K, Semebeous A, et al. Invasiveness of human endometrial stromal cells is promoted by decidualisation and by trophoblast signals. Hum Reprod 2010;25:862–73.
- Bazer FW, Wu G, Spencer Th E, et al. Novel pathways for implantation and establishment and maintenance of pregnancy in mammals. Mol Hum Reprod 2010;16:135–52.
- Arck P, Hansen PJ, Jesivewiz WM, et al. Progesterone during pregnancy: endocrine-immune crosstalk in mammalien species and the role of stress. Am J Reprod Immunol 2007;58:268–79.
- Ark BC, Rüde M, Rose N, et al. Early risk factors for miscarriage: a prospective cohort study in pregnant women. Reprod Biomed Online 2008;17:101–13.
- Blois M, Joachim R, Kandic J, et al. Depletion of CD 8+cells abolishes the pregnancy protective effect of progesterone substitution with dydrogesterone in mice by altering Th1/Th2-cytokine profile. J Immunol 2004;172:5893–9.
- Joachim R, Zenelassen C, Bolgar B, et al. The progesterone-derivative dydrogesterone abrogates murine stress-triggered abortion by inducing aTh2-biased local immune response. Steroids 2003;68:931–40.
- Matalliotakis M, Trivli A. Preeclampsia through the eyes of the women. EC Gynecol 2017;6:23–4.
- Aronow WS. Hypertensive disorders in pregnancy. Ann Transl Med 2017;5:266–71.
- Zang J, Zeisler J, Hatch MC, Berkowitz G. Epidemiology of pregnancy-induced hypertension. Epidemiol Rev 1997;19:218–32.
- Zainul RMR, Lin JE, Nawovi NH, et al. A pilot study to determine whether progestogen supplementation during the first trimester will reduce the incidence of gestational hypertension in primigravidae. Gynecol Endocrinol 2014;30:217–20.
- Zainul RMR, Schindler AE. Review on the role of progestogen (Dydrogesterone) in the prevention of gestational hypertension. Horm Mol Biol Clin Investig 2016;27:73–6.
- Ali A, Bt Ahmad MFB, Kwang NB, et al. Dydrogesterone support following assisted reproductive technique (ART) reduces the risk of preeclampsia. Horm Mol Biol Clin Investig 2016;27:93–6.
- Tskhay V, Kortun NM, Schindler AE. Successful prevention of preeclampsia in a high-risk pregnancy using the progestogen dydrogesterone: a clinical case. Horm Mol Biol Clin Investig 2016;27:85–8.